Anavex Life Sciences Corp (AVXL)
3.82
-0.07
(-1.80%)
USD |
NASDAQ |
May 10, 16:00
3.82
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Enterprise Value: 175.65M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 175.65M |
| May 08, 2024 | 160.87M |
| May 07, 2024 | 171.55M |
| May 06, 2024 | 171.55M |
| May 03, 2024 | 172.37M |
| May 02, 2024 | 164.98M |
| May 01, 2024 | 159.23M |
| April 30, 2024 | 155.95M |
| April 29, 2024 | 155.95M |
| April 26, 2024 | 138.70M |
| April 25, 2024 | 134.60M |
| April 24, 2024 | 136.24M |
| April 23, 2024 | 158.41M |
| April 22, 2024 | 158.41M |
| April 19, 2024 | 166.62M |
| April 18, 2024 | 168.26M |
| April 17, 2024 | 190.43M |
| April 16, 2024 | 194.54M |
| April 15, 2024 | 203.57M |
| April 12, 2024 | 208.91M |
| April 11, 2024 | 221.64M |
| April 10, 2024 | 208.50M |
| April 09, 2024 | 216.71M |
| April 08, 2024 | 216.71M |
| April 05, 2024 | 219.17M |
| Date | Value |
|---|---|
| April 04, 2024 | 224.10M |
| April 03, 2024 | 235.59M |
| April 02, 2024 | 229.03M |
| April 01, 2024 | 268.44M |
| March 28, 2024 | 274.19M |
| March 27, 2024 | 271.72M |
| March 26, 2024 | 253.66M |
| March 25, 2024 | 229.85M |
| March 22, 2024 | 238.88M |
| March 21, 2024 | 275.83M |
| March 20, 2024 | 276.65M |
| March 19, 2024 | 253.66M |
| March 18, 2024 | 252.02M |
| March 15, 2024 | 275.83M |
| March 14, 2024 | 278.29M |
| March 13, 2024 | 298.00M |
| March 12, 2024 | 283.22M |
| March 11, 2024 | 282.40M |
| March 08, 2024 | 303.75M |
| March 07, 2024 | 282.40M |
| March 06, 2024 | 268.44M |
| March 05, 2024 | 265.16M |
| March 04, 2024 | 275.83M |
| March 01, 2024 | 289.79M |
| February 29, 2024 | 278.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
93.44M
Minimum
Aug 05 2019
2.014B
Maximum
Jun 28 2021
537.25M
Average
495.28M
Median
Enterprise Value Benchmarks
| Ventyx Biosciences Inc | 12.58M |
| Checkpoint Therapeutics Inc | 50.74M |
| Amicus Therapeutics Inc | 2.899B |
| Insmed Inc | 4.292B |
| InfuSystems Holdings Inc | 189.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.622M |
| Total Expenses (Quarterly) | 11.29M |
| EPS Diluted (Quarterly) | -0.11 |
| Earnings Yield | -14.40% |